CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH

临床试验：针对患有以下疾病的患者进行肽疫苗接种的 II 期试验

• 批准号: 7951467
• 负责人: Craig Lee Slingluff
• 金额: $ 2.34万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951467
• 关键词: CD4 Positive T Lymphocytes; CD8B1 gene; Clinical; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Data; Epitopes; Funding; Grant; Helper-Inducer T-Lymphocyte; Immune response; Institution; MHC Class I Genes; Measurable; Multicenter Studies; Outcome; Patients; Peptide Vaccines; Peptides; Phase II Clinical Trials; Phenotype; Randomized; Research; Research Personnel; Resources; Secondary Immunization; Source; Staging; T-Lymphocyte; United States National Institutes of Health; Vaccination; Vaccines; melanoma; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, multicenter study for patients with measurable, stage IV melanoma. This study will: (a) estimate whether the addition of helper peptides to class I MHC-restricted peptides augments T-cell responses to the Class I MHC-restricted peptides, (b) characterize the phenotype of vaccine-induced CD8+ T cells, (c) determine the helper T-cell response to each helper peptide, (d) obtain preliminary data on whether booster vaccination every three months may maintain immune responses to a peptide vaccine, and (e) obtain preliminary data on whether cellular immune responses to a 12-epitope peptide vaccine correlates with clinical outcome.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项针对可测量的IV期黑色素瘤患者的随机多中心研究。 这项研究将：（a）估计在I类MHC限制肽中添加辅助肽是否会增加对I类MHC限制肽的T细胞反应，（b）表征疫苗诱导的CD8+ T细胞的表型c）确定对每种辅助肽的辅助T细胞反应，（d）获得有关是否每三个月增加一次促进疫苗接种是否可以维持对肽疫苗的免疫反应的初步数据，并且（e）获得有关细胞免疫反应是否对A的初步数据12- EPTOPE肽疫苗与临床结果相关。